KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) EBT Margin: 2009-2025

Historic EBT Margin for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to 16.01%.

  • Acadia Pharmaceuticals' EBT Margin rose 51.00% to 16.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 26.14%, marking a year-over-year increase of 1142.00%. This contributed to the annual value of 26.94% for FY2024, which is 3397.00% up from last year.
  • As of Q3 2025, Acadia Pharmaceuticals' EBT Margin stood at 16.01%, which was up 5.32% from 15.20% recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year EBT Margin high stood at 62.05% for Q4 2024, and its period low was -97.52% during Q1 2022.
  • For the 3-year period, Acadia Pharmaceuticals' EBT Margin averaged around 9.47%, with its median value being 15.20% (2025).
  • Its EBT Margin has fluctuated over the past 5 years, first slumped by 3,518bps in 2022, then surged by 5,958bps in 2023.
  • Over the past 5 years, Acadia Pharmaceuticals' EBT Margin (Quarterly) stood at -32.81% in 2021, then soared by 289bps to -29.92% in 2022, then spiked by 4,711bps to 17.18% in 2023, then surged by 4,486bps to 62.05% in 2024, then soared by 51bps to 16.01% in 2025.
  • Its last three reported values are 16.01% in Q3 2025, 15.20% for Q2 2025, and 11.38% during Q1 2025.